A very warm welcome to the September 1st, 2025 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”.  EURETINA are delighted for an up-to-date summary briefs on a range of topics of interest to retinal clinicians, specialists and researchers across Europe. This resource was designed to accommodate the very busy schedules of all our members by providing them with a short overview of some new developments and announcements in our field over recent weeks.

The current issue highlights a number of research activities, clinical / regulatory milestones, and market / business developments in our field, including  a “ concept elicitation study” on qualitative interviews for Retinitis pigmentosa (RP) and Choroideremia (CHM); a systematic review of retinal gene therapy on the impact of route administrations and on serious adverse events (SAEs), and; a new gene therapy candidate – “OPGxBEST1” – reporting a FDA clearance from Opus Genetics for an investigational new drug application (IND) for the treatment of bestrophin-1-related IRD.

As in previous issues we have incorporated a feedback section where you can comment on any of the news items or articles under discussion and we very much welcome all contributions.  Previous articles and issues can be found in the archive section on this website.

As always, your increased interaction within the EURETINA web community serves to expand your professional network and keep you up to date with the latest initiatives, activities and research in your field. Our hope is that such cross-fertilisation in an active web-based platform, including our LinkedIn page, will lead to increased collaborative opportunities and ultimately to improved patient care. All readers are invited to submit comments or responses to any of the stories featured and we look forward to hearing from you over the coming month.

Best wishes,

Dr. Gearóid Tuohy

B.Sc., Ph.D., M.Sc. (Clinical Trial Management)

EURETINA

A very warm welcome to the August 15^th, 2025 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”.  EURETINA are delighted to continue our delivery of up-to-date summary briefs on a range of topics of interest to retinal clinicians, specialists and researchers across Europe. This resource is designed to accommodate the very busy schedules of all our members by providing them with a short overview of some new developments and announcements in our field over recent weeks.

The current issue highlights a number of research activities, clinical / regulatory milestones, and market / business developments in our field, including  a new treatment outcome and natural history registry for inherited retinal disease (IRD) – presented as “THE FIGHT INHERITED RETINAL BLINDNESS! PROJECT”; a review of fundus autofluorescence (FAF) underscoring an indispensable technology for the diagnosis, monitoring and outcome measures of numerous retinal diseases, and; an announcement of 60-week results from 4D-150 “SPECTRA” treatment for DME Phase 3 data reports sustained visual acuity gains.

As in previous issues we have incorporated a feedback section where you can comment on any of the news items or articles under discussion and we very much welcome all contributions.  Previous articles and issues can be found in the archive section on this website.

As always, your increased interaction within the EURETINA web community serves to expand your professional network and keep you up to date with the latest initiatives, activities and research in your field. Our hope is that such cross-fertilisation in an active web-based platform, including our LinkedIn page, will lead to increased collaborative opportunities and ultimately to improved patient care. All readers are invited to submit comments or responses to any of the stories featured and we look forward to hearing from you over the coming month.

Best wishes, 

Dr. Gearóid Tuohy

B.Sc., Ph.D., M.Sc. (Clinical Trial Management)

EURETINA

A very warm welcome to the August 4^th, 2025 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”.  EURETINA are delighted to continue our delivery of up-to-date summary briefs on a range of topics of interest to retinal clinicians, specialists and researchers across Europe. This resource is designed to accommodate the very busy schedules of all our members by providing them with a short overview of some new developments and announcements in our field over recent weeks.

The current issue highlights a number of research activities, clinical / regulatory milestones, and market / business developments in our field, including a small study of severe variants of ABCA4 reports a new genotype–phenotype correlation with Early-Onset Severe Retinal Dystrophy (EOSRD); a clinical study of >3,500 IRD patients reports novel genotype-phenotype associations using optical coherence tomography (OCT) imaging, and; Beacon Therapeutics announce the completion of enrolment for the Phase 2/3 trial for “laru-zova”, for the treatment of XLRP.

As in previous issues we have incorporated a feedback section where you can comment on any of the news items or articles under discussion and we very much welcome all contributions.  Previous articles and issues can be found in the archive section on this website.

As always, your increased interaction within the EURETINA web community serves to expand your professional network and keep you up to date with the latest initiatives, activities and research in your field. Our hope is that such cross-fertilisation in an active web-based platform, including our LinkedIn page, will lead to increased collaborative opportunities and ultimately to improved patient care. All readers are invited to submit comments or responses to any of the stories featured and we look forward to hearing from you over the coming month.

Best wishes,

Dr. Gearóid Tuohy

B.Sc., Ph.D., M.Sc. (Clinical Trial Management)

EURETINA

A very warm welcome to the July 21^st, 2025 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”.  EURETINA are delighted to continue our delivery of up-to-date summary briefs on a range of topics of interest to retinal clinicians, specialists and researchers across Europe. This resource is designed to accommodate the very busy schedules of all our members by providing them with a short overview of some new developments and announcements in our field over recent weeks.

The current issue highlights a number of research activities, clinical / regulatory milestones, and market / business developments in our field, including the first report of a beta-tubulin 4B gene variant (TUBB4B) with RP, late-onset and progressive sensorineural hearing loss; a quantitative choroidal assessment may be valuable for using other standard metrics for retinal clinical trial evaluations, and finally; an announcement from Astena Therapeutics on the expansion of a Phase 1 / 2 study into a continuous Phase 1 / 2 / 3 trial, agreed by U.S. Food and Drug Administration (FDA).

As in previous issues we have incorporated a feedback section where you can comment on any of the news items or articles under discussion and we very much welcome all contributions.  Previous articles and issues can be found in the archive section on this website.

As always, your increased interaction within the EURETINA web community serves to expand your professional network and keep you up to date with the latest initiatives, activities and research in your field. Our hope is that such cross-fertilisation in an active web-based platform, including our LinkedIn page, will lead to increased collaborative opportunities and ultimately to improved patient care. All readers are invited to submit comments or responses to any of the stories featured and we look forward to hearing from you over the coming month.

Best wishes,

Dr. Gearóid Tuohy

B.Sc., Ph.D., M.Sc. (Clinical Trial Management)

EURETINA

A very warm welcome to the July 7^th, 2025 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”.  EURETINA are delighted to continue our delivery of up-to-date summary briefs on a range of topics of interest to retinal clinicians, specialists and researchers across Europe. This resource is designed to accommodate the very busy schedules of all our members by providing them with a short overview of some new developments and announcements in our field over recent weeks.

The current issue highlights a number of research activities, clinical / regulatory milestones, and market / business developments in our field, including an AI tool  -“Eye2Gene” – which performed a genetic diagnosis better results from any single human ophthalmic expert; a GWAS study indicating that instant coffee may increase the risk of AMD, and reducing instant coffee intake can prevent dry AMD, and; summary results from a Phase II trial showing that sub-cutaneous injections at home may provide a paradigm shift of anti-VEGF treatment for AMD and DME.

As in previous issues we have incorporated a feedback section where you can comment on any of the news items or articles under discussion and we very much welcome all contributions.  Previous articles and issues can be found in the archive section on this website.

As always, your increased interaction within the EURETINA web community serves to expand your professional network and keep you up to date with the latest initiatives, activities and research in your field. Our hope is that such cross-fertilisation in an active web-based platform, including our LinkedIn page, will lead to increased collaborative opportunities and ultimately to improved patient care. All readers are invited to submit comments or responses to any of the stories featured and we look forward to hearing from you over the coming month.

Best wishes,

Dr. Gearóid Tuohy

B.Sc., Ph.D., M.Sc. (Clinical Trial Management)

EURETINA

A very warm welcome to the June 23^rd, 2025 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”.  EURETINA are delighted to continue our delivery of up-to-date summary briefs on a range of topics of interest to retinal clinicians, specialists and researchers across Europe. This resource is designed to accommodate the very busy schedules of all our members by providing them with a short overview of some new developments and announcements in our field over recent weeks.

The current issue highlights a number of research activities, clinical / regulatory milestones, and market / business developments in our field, including the first genome-wide association study (GWAS) on AMD involving reticular pseudodrusen (RPD), providing a clear relationship between RPD and the ARMS2-HTRA1 locus; a Swedish independent clinical study reports a 3% increased risk of stroke within 90 days of anti-VEGF treatments, and finally; an announcement by VeonGen Therapeutics GmbH re-branding of the company (previously ViGeneron) and the progression of treatments for Stargardt’s disease and retinitis pigmentosa.

As in previous issues we have incorporated a feedback section where you can comment on any of the news items or articles under discussion and we very much welcome all contributions.  Previous articles and issues can be found in the archive section on this website.

As always, your increased interaction within the EURETINA web community serves to expand your professional network and keep you up to date with the latest initiatives, activities and research in your field. Our hope is that such cross-fertilisation in an active web-based platform, including our LinkedIn page, will lead to increased collaborative opportunities and ultimately to improved patient care. All readers are invited to submit comments or responses to any of the stories featured and we look forward to hearing from you over the coming month.

Best wishes,

Dr. Gearóid Tuohy

B.Sc., Ph.D., M.Sc. (Clinical Trial Management)

EURETINA

A very warm welcome to the June 9^th, 2025 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”.  EURETINA are delighted to continue our delivery of up-to-date summary briefs on a range of topics of interest to retinal clinicians, specialists and researchers across Europe. This resource is designed to accommodate the very busy schedules of all our members by providing them with a short overview of some new developments and announcements in our field over recent weeks.

The current issue highlights a number of research activities, clinical / regulatory milestones, and market / business developments in our field, including a proposed barring of The Lancet, the New England Journal of Medicine, and the Journal of the American Medical Association, by the US Department of Health & Human Services (HHS); patient recruitment for a Phase 3 trial of vorolanib intravitreal insert using a tyrosine kinase inhibitor (TKI) to evaluate for wet age-related macular degeneration (wet AMD) and, finally;   receipt of a European CE-mark (Class IIa) by deepeye Medical (Munich) providing the first predictive AI tool for retinal therapy planning.

As in previous issues we have incorporated a feedback section where you can comment on any of the news items or articles under discussion and we very much welcome all contributions.  Previous articles and issues can be found in the archive section on this website.

As always, your increased interaction within the EURETINA web community serves to expand your professional network and keep you up to date with the latest initiatives, activities and research in your field. Our hope is that such cross-fertilisation in an active web-based platform, including our LinkedIn page, will lead to increased collaborative opportunities and ultimately to improved patient care. All readers are invited to submit comments or responses to any of the stories featured and we look forward to hearing from you over the coming month.

Best wishes,

Dr. Gearóid Tuohy

B.Sc., Ph.D., M.Sc. (Clinical Trial Management)

EURETINA

A very warm welcome to the May 26^th, 2025 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”.  EURETINA are delighted to continue our delivery of up-to-date summary briefs on a range of topics of interest to retinal clinicians, specialists and researchers across Europe. This resource is designed to accommodate the very busy schedules of all our members by providing them with a short overview of some new developments and announcements in our field over recent weeks.

The current issue highlights a number of research activities, clinical / regulatory milestones, and market / business developments in our field, including a research survey to evaluate patient perspectives and considerations regarding the application of AI in the diagnosis of IRDs; clinical research on patients with infantile nystagmus syndrome (INS), across several inherited ocular diseases, providing significant support for counselling and on-going clinical trials, and finally; an announcement by Ashvattha Therapeutics Inc., presenting positive Phase 2 results at ARVO for a subcutaneous migaldendranib treatment, delivered via a hydroxyl dendrimer for retinal vascular disease.

As in previous issues we have incorporated a feedback section where you can comment on any of the news items or articles under discussion and we very much welcome all contributions.  Previous articles and issues can be found in the archive section on this website.

As always, your increased interaction within the EURETINA web community serves to expand your professional network and keep you up to date with the latest initiatives, activities and research in your field. Our hope is that such cross-fertilisation in an active web-based platform, including our LinkedIn page, will lead to increased collaborative opportunities and ultimately to improved patient care. All readers are invited to submit comments or responses to any of the stories featured and we look forward to hearing from you over the coming month.

Best wishes,

Dr. Gearóid Tuohy

B.Sc., Ph.D., M.Sc. (Clinical Trial Management)

EURETINA

A very warm welcome to the May 12^th, 2025 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”.  EURETINA are delighted to continue our delivery of up-to-date summary briefs on a range of topics of interest to retinal clinicians, specialists and researchers across Europe. This resource is designed to accommodate the very busy schedules of all our members by providing them with a short overview of some new developments and announcements in our field over recent weeks.

The current issue highlights a number of research activities, clinical / regulatory milestones, and market / business developments in our field, including a new study on a genome-wide association of central serous chorioretinopathy (CSC), varicose veins and glaucoma identifying a missense variant in PTPRB gene; a natural history of PCARE-associated retinopathy, highlighting genetics, clinical characteristics and time-to-event curves for development of atrophy, and finally; an announcement by Opus Genetics Inc., on 12-month summary results for OPGx-LCA5 – an experimental gene therapy treatment of LCA5 retinal disease.

As in previous issues we have incorporated a feedback section where you can comment on any of the news items or articles under discussion and we very much welcome all contributions.  Previous articles and issues can be found in the archive section on this website.

As always, your increased interaction within the EURETINA web community serves to expand your professional network and keep you up to date with the latest initiatives, activities and research in your field. Our hope is that such cross-fertilisation in an active web-based platform, including our LinkedIn page, will lead to increased collaborative opportunities and ultimately to improved patient care. All readers are invited to submit comments or responses to any of the stories featured and we look forward to hearing from you over the coming month.

Best wishes,

Dr. Gearóid Tuohy, B.Sc., Ph.D., M.Sc. (Clinical Trial Management)

EURETINA

A very warm welcome to the April 28^th, 2025 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”.  EURETINA are delighted to continue our delivery of up-to-date summary briefs on a range of topics of interest to retinal clinicians, specialists and researchers across Europe. This resource is designed to accommodate the very busy schedules of all our members by providing them with a short overview of some new developments and announcements in our field over recent weeks.

The current issue highlights a number of research activities, clinical / regulatory milestones, and market / business developments in our field, including research providing new insight into how individual genotypes can influence phenotypic features in neuronal ceroid lipofuscinosis (NCL)-associated retinal disease; a new “CONSORT 2025 statement” announcing an expanded checklist to optimally conduct high-quality research on randomised trials, and; an announcement from LumiThera Inc., obtaining FDA authorisation in the US on a photo-biomodulation (PBT) medical device – “Valeda” –  for the treatment of dry AMD.

As in previous issues we have incorporated a feedback section where you can comment on any of the news items or articles under discussion and we very much welcome all contributions.  Previous articles and issues can be found in the archive section on this website.

As always, your increased interaction within the EURETINA web community serves to expand your professional network and keep you up to date with the latest initiatives, activities and research in your field. Our hope is that such cross-fertilisation in an active web-based platform, including our LinkedIn page, will lead to increased collaborative opportunities and ultimately to improved patient care. All readers are invited to submit comments or responses to any of the stories featured and we look forward to hearing from you over the coming month.

Best wishes,

Dr. Gearóid Tuohy

B.Sc., Ph.D., M.Sc. (Clinical Trial Management)

EURETINA